CEBPZ and leukemia: Accordingly, we showed an improved LFS but not OS in our patients receiving allogeneic HSCT in CR1, consistent with results from other studies employing frontline HSCT in CBF-AML, either because of institute policy or guided by minimal residual leukemia.29, 30, 33 With improvement in supportive care and advent of reduced-intensity, the indications and potential benefit of upfront HSCT for selected CBF-AML patients, particularly those with unfavorable gene mutation profiles, should be explored.